Genetic Technologies announces the Company has released its novel Comprehensive Risk Assessment test that covers 100% of women at risk of developing breast and ovarian cancer. The innovative test, available to all women above the age of 30, assesses a woman’s risk of cancer due to hereditary, including those with common gene mutations, and sporadic disease. Launched at the inaugural “Know Your Risk” event in California, USA, the event provided invaluable insights of the role of genomics in women’s health. GTG’s CEO, Simon Morriss, said “We are incredibly proud to have been part of this ‘Know Your Risk’ event which underscored the importance of genetic testing and risk assessment in transforming women’s health, inspiring attendees to advocate for their health and well-being proactively. We are also very fortunate and to have the opportunity to launch this unique risk assessment test in the presence of such a wonderful group of people”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GENE:
- Genetic Technologies, Humanise Health host ‘Know Your Risk’ event
- Genetic Technologies files to sell 30M ordinary shares for holders
- Genetic Technologies, Wellworks for You sign B2B sales, marketing deal
- Genetic Technologies Forges Major US Wellness Partnership
- Genetic Technologies reports Q3 cash receipts A$1.8M